CONFIDENTIAL TREATMENT REQUESTED AMENDMENT NO. 4 TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 27th, 2014 • OvaScience, Inc. • Pharmaceutical preparations
This Amendment No. 4 (this “Amendment”) to the Exclusive License Agreement between OvaScience, Inc. (“Company”) and The General Hospital Corporation (“Hospital”), dated June 27, 2011 (the “Agreement”), is effective upon signing by both parties hereto. Capitalized terms used but not defined within this Amendment have the meanings specified within the Agreement.
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • February 27th, 2014 • OvaScience, Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (this “Agreement”) is made and entered into effective as of December 18, 2013 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and OVAXON, LLC, a Delaware limited liability company having a place of business at 215 First Street, Suite 240, Cambridge, MA 02142 (“OvaXon”). Intrexon and OvaXon may be referred to herein individually as a “Party”, and collectively as the “Parties.”
AMENDMENT NO. 3 TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 27th, 2014 • OvaScience, Inc. • Pharmaceutical preparations
This Amendment No. 3 (this “Amendment”) to the Exclusive License Agreement between OvaScience, Inc. (“Company”) and The General Hospital Corporation (“Hospital”), dated June 27, 2011 (the “Agreement”), is effective upon signing by both parties hereto. Capitalized terms used but not defined within this Amendment have the meanings specified within the Agreement.
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • February 27th, 2014 • OvaScience, Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (this “Agreement”) is made and entered into effective as of December 18, 2013 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and OVASCIENCE, INC., a Delaware corporation having a place of business at 215 First Street, Suite 240, Cambridge, MA 02142 (“OvaScience”). Intrexon and OvaScience may be referred to herein individually as a “Party”, and collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 27th, 2014 • OvaScience, Inc. • Pharmaceutical preparations
This Amendment No. 2 (this “Amendment”) to the Exclusive License Agreement between OvaScience, Inc. (“Company”) and The General Hospital Corporation (“Hospital”), dated June 27, 2011 (the “Agreement”), is effective upon signing by both parties hereto. Capitalized terms used but not defined within this Amendment have the meanings specified within the Agreement.
INTELLECTUAL PROPERTY LICENSE AGREEMENTIntellectual Property License Agreement • February 27th, 2014 • OvaScience, Inc. • Pharmaceutical preparations • New York
This INTELLECTUAL PROPERTY LICENSE AGREEMENT (this “Agreement”) is entered into as of December 18, 2013 (the “Effective Date”), by and between OvaXon, LLC, a limited liability company organized under the laws of the State of Delaware and having offices at 215 First Street, Suite 240, Cambridge, MA 02142 (hereinafter, “OvaXon” or “Licensee”) and OvaScience, Inc., a Delaware corporation having offices at 215 First Street, Suite 240, Cambridge, MA 02142 (“OvaScience”).
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT NO. 5 TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 27th, 2014 • OvaScience, Inc. • Pharmaceutical preparations
This Amendment No. 5 (this “Amendment”) to the Exclusive License Agreement between OvaScience, Inc. (“Company”) and The General Hospital Corporation (“Hospital”), dated June 27, 2011 (the “Agreement”), is effective upon signing by both parties hereto. Capitalized terms used but not defined within this Amendment have the meanings specified within the Agreement.
RE: Separation AgreementSeparation Agreement • February 27th, 2014 • OvaScience, Inc. • Pharmaceutical preparations • Massachusetts
The purpose of this letter agreement (the “Agreement”) is to set forth the terms regarding your separation of employment from OvaScience, Inc. (the “Company”). As more fully set forth below, the Company desires to provide you with separation benefits in exchange for certain agreements by you. This Agreement shall become effective on the eighth (8th) day following your acceptance of it (the “Effective Date”) as described below.
